Prolastin-C market forecast points to growth through 2030
The Prolastin-C market is projected to expand through 2030 as research spending rises, respiratory disease burden persists and hospitals keep using specialized immunotherapy approaches. North America led the market in 2025, while Asia-Pacific is expected to grow fastest over the forecast period.
Why it matters: - Prolastin-C is tied to treatment for alpha-1 antitrypsin deficiency, a genetic disorder that can lead to severe lung disease. - The market outlook reflects broader demand for respiratory care and oncology-related therapies in hospital settings. - Growth in the segment could benefit from continued investment in advanced treatments, personalized care and combination therapy approaches.
What happened: - The Business Research Company released a Prolastin-C market forecast covering the period to 2030. - The report says the market is being shaped by cancer treatment advances, respiratory care trends and hospital oncology adoption. - The company says the market gained traction historically after approval for metastatic renal cell carcinoma and early use of immunotherapy in hospital oncology settings. - The report places North America as the largest market in 2025. - The report projects Asia-Pacific as the fastest-growing region during the forecast period.
The details: - Prolastin-C is a purified alpha-1 proteinase inhibitor, also called alpha-1 antitrypsin, extracted from human plasma. - The therapy is used as augmentation treatment for patients with alpha-1 antitrypsin deficiency. - Prolastin-C helps raise alpha-1 antitrypsin levels in the blood and lungs. - The treatment protects lung tissue from damage caused by neutrophil elastase, an enzyme linked to inflammation and tissue harm. - The report points to rising respiratory infections as a demand driver. - Respiratory infections affect the nose, throat, airways and lungs and can be caused by viruses, bacteria and fungi. - The report cites emerging viral mutations, seasonal changes, weaker immune defenses, pollution and higher human mobility as contributors to infection growth. - Prolastin-C is positioned as a replacement therapy for deficient AAT protein in AATD-related COPD. - The report says the therapy can reduce lung inflammation, limit protease-driven tissue degradation and support lung function. - Australia recorded 474 asthma-related deaths in 2023, compared with 473 in 2022, as one example of the ongoing respiratory disease burden. - Rising R&D spending is another market driver. - U.S. research and development spending rose from $892 billion in 2022 to $940 billion in 2023, according to the National Center for Science and Engineering Statistics. - The report says that higher R&D spending supports clinical trials, drug formulation work and dosing optimization for Prolastin-C. - The geographic scope of the analysis includes Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East and Africa. - Download a free sample of the market report - View the full market report
Between the lines: - The forecast blends oncology and respiratory care themes, suggesting the market narrative is broader than a single disease category. - The report’s emphasis on hospital-based IL-2 administration, cytokine immunotherapy and combination therapy signals continued reliance on specialized treatment pathways. - The regional split implies mature demand in North America and faster expansion potential in markets where healthcare access is still improving.
What's next: - The report expects growth to continue through 2030 as oncology centers expand and personalized cancer care becomes more common. - Key trends to watch include sustained cytokine immunotherapy use, niche immuno-oncology applications and integration with other cancer therapies. - The report’s 2026 edition adds market attractiveness scoring, TAM analysis, company scoring matrix graphics, Excel forecasting dashboards, market hotspot infographics and updated graphics and tables. - The Business Research Company lists Saumya Sahay as a contact for more information at marketing@tbrc.info.
Disclaimer: This article was produced by AGP Wire with the assistance of artificial intelligence based on original source content and has been refined to improve clarity, structure, and readability. This content is provided on an “as is” basis. While care has been taken in its preparation, it may contain inaccuracies or omissions, and readers should consult the original source and independently verify key information where appropriate. This content is for informational purposes only and does not constitute legal, financial, investment, or other professional advice.
Sign up for:
Market Forecast Analysis
The daily local news briefing you can trust. Every day. Subscribe now.
Check Your Email!
We sent a one-time activation link to: .
Confirm it's you by clicking the email link.
If the email is not in your inbox, check spam or try again.
Welcome back!
is already signed up. Check your inbox for updates.